Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5309167 | 0.85 | MAPT (0.51) | MAPTMAPK1POLBVCAM1L3MBTL1 | |
| SCHEMBL2007502 | 0.81 | LMNA (0.49) | MAPTMAPK1POLBVCAM1L3MBTL1 | |
| SCHEMBL72187 | 0.81 | MAPT (0.56) | MAPTMAPK1POLBVCAM1L3MBTL1 | |
| SCHEMBL16545190 | 0.80 | MAPT (0.51) | MAPTMAPK1POLBVCAM1L3MBTL1 | |
| SCHEMBL18038271 | 0.76 | MAPK1 (0.57) | MAPTMAPK1POLBVCAM1L3MBTL1 | |
| SCHEMBL2818590 | 0.76 | LMNA (0.52) | MAPTMAPK1POLBLMNAKDM4E | |
| SCHEMBL15878470 | 0.75 | MAPT (0.47) | MAPTMAPK1POLBVCAM1L3MBTL1 | |
| SCHEMBL15889718 | 0.75 | MAPT (0.40) | MAPTMAPK1POLBVCAM1L3MBTL1 | |
| SCHEMBL11377331 | 0.75 | MAPK1 (0.59) | MAPTMAPK1POLBVCAM1L3MBTL1 | |
| SCHEMBL16532811 | 0.74 | MAPT (0.46) | MAPTMAPK1POLBVCAM1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562060-B2 | Heterocyclic pyridone compound, and intermediate, preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2017-02-07 | — | — | US | disclosed |
| US-20140206679-A1 | HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2014-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206679-A1 | HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | MET, PDXK, FLT3 | MAPT 2852/4885MAPK1 204/4885POLB 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.